KM Financial Solutions | FOCUS-Takeda CEO prescribes surgical R&D cuts after $62 bln Shire deal
17347
post-template-default,single,single-post,postid-17347,single-format-standard,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-child-theme-ver-1.0.0,qode-theme-ver-11.2,qode-theme-bridge,wpb-js-composer js-comp-ver-5.2.1,vc_responsive
 

FOCUS-Takeda CEO prescribes surgical R&D cuts after $62 bln Shire deal

FOCUS-Takeda CEO prescribes surgical R&D cuts after $62 bln Shire deal

* Takeda boss to raise bar for pipeline drugs after Shire
deal

No Comments

Sorry, the comment form is closed at this time.